Loading...
Loading...

Go to the content (press return)

HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02)

Author
Mothe, B.; Rosas, M.; Coll, P.; Manzardo, C.; Puertas, M.; Morón, S.; Llano, A.; Alarcón, Y.; Gómez Melis, Guadalupe; Langohr, K.
Type of activity
Journal article
Journal
Frontiers in Immunology
Date of publication
2020-05-06
Volume
11
DOI
10.3389/fimmu.2020.00823
Repository
http://hdl.handle.net/2117/331652 Open in new window
URL
https://www.frontiersin.org/articles/10.3389/fimmu.2020.00823/full Open in new window
Abstract
Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enrolling 15 early-treated HIV-1-infected individuals, testing the combination of the histone deacetylase inhibitor romidepsin as a latency-reversing agent and the MVA.HIVconsv vaccine. Romidepsin treatment resulte...
Citation
Mothe, B. [et al.]. HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02). "Frontiers in Immunology", 6 Maig 2020, vol. 11.
Keywords
HDAC inhibitor, HIVconsv, early-treatment, kick&kill strategy, romidepsin
Group of research
GRBIO - Biostatistics and Bioinformatics Research Group

Participants

Attachments